Small mol­e­cules, bi­o­log­ics and now gene ther­a­pies: Ger­many's Evotec adds an­oth­er feath­er to its R&D cap

Ger­man drug dis­cov­ery com­pa­ny Evotec — which has a thriv­ing rolodex of bio­phar­ma part­ners such as Bay­er, Boehringer In­gel­heim, No­var­tis, No­vo Nordisk, Pfiz­er, Sanofi, and Take­da — is now ven­tur­ing in­to gene ther­a­pies.

The com­pa­ny swal­lowed Seat­tle-based Just Bio­ther­a­peu­tics, a com­pa­ny fo­cused on re­duc­ing the cost of man­u­fac­tur­ing pro­tein ther­a­pies last year. It is now set­ting up a ded­i­cat­ed R&D site for gene ther­a­pies in Aus­tria, in an ef­fort to achieve a “modal­i­ty-ag­nos­tic” reper­toire — small mol­e­cules, bi­o­log­ics and now gene ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER